UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Maximus, Inc. (NYSE:MMS - Free Report) by 8.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,754 shares of the health services provider's stock after selling 11,779 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.21% of Maximus worth $11,622,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. V Square Quantitative Management LLC purchased a new position in shares of Maximus in the third quarter valued at approximately $25,000. GAMMA Investing LLC boosted its stake in Maximus by 224.5% during the 2nd quarter. GAMMA Investing LLC now owns 344 shares of the health services provider's stock worth $29,000 after purchasing an additional 238 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Maximus by 201.5% during the second quarter. Blue Trust Inc. now owns 392 shares of the health services provider's stock worth $33,000 after buying an additional 262 shares in the last quarter. Archer Investment Corp raised its position in shares of Maximus by 8,788.9% in the second quarter. Archer Investment Corp now owns 800 shares of the health services provider's stock valued at $69,000 after buying an additional 791 shares during the last quarter. Finally, Ariadne Wealth Management LP purchased a new position in shares of Maximus in the second quarter worth about $90,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.
Maximus Price Performance
Shares of NYSE:MMS traded down $1.14 during midday trading on Friday, hitting $72.70. The company had a trading volume of 655,672 shares, compared to its average volume of 1,196,237. The business's 50-day simple moving average is $84.71 and its 200-day simple moving average is $87.13. The stock has a market cap of $4.38 billion, a price-to-earnings ratio of 14.54 and a beta of 0.73. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.49 and a quick ratio of 1.49. Maximus, Inc. has a twelve month low of $71.75 and a twelve month high of $93.97.
Maximus Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Saturday, November 30th. Shareholders of record on Friday, November 15th were paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.65%. The ex-dividend date was Friday, November 15th. Maximus's dividend payout ratio (DPR) is presently 24.00%.
Analyst Upgrades and Downgrades
Separately, StockNews.com cut shares of Maximus from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th.
View Our Latest Research Report on MMS
Insider Transactions at Maximus
In other news, insider Michelle F. Link sold 2,208 shares of Maximus stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $73.83, for a total transaction of $163,016.64. Following the sale, the insider now owns 6,567 shares of the company's stock, valued at approximately $484,841.61. The trade was a 25.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.40% of the company's stock.
Maximus Company Profile
(
Free Report)
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Further Reading
Before you consider Maximus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.
While Maximus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.